MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.

Animals Apoptosis Burkitt Lymphoma / genetics Cell Cycle Checkpoints Cell Cycle Proteins / genetics Cell Proliferation Chromosome Aberrations Chromosomes, Human, Pair 1 / genetics Gene Expression Regulation, Neoplastic Humans Mice Mutation Proto-Oncogene Proteins / genetics Tumor Cells, Cultured Tumor Suppressor Protein p53 / genetics Xenograft Model Antitumor Assays

Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 06 2019
Historique:
received: 06 11 2018
revised: 11 03 2019
accepted: 15 04 2019
pubmed: 20 4 2019
medline: 12 3 2020
entrez: 20 4 2019
Statut: ppublish

Résumé

Oncogenic MYC activation promotes proliferation in Burkitt lymphoma, but also induces cell-cycle arrest and apoptosis mediated by p53, a tumor suppressor that is mutated in 40% of Burkitt lymphoma cases. To identify molecular dependencies in Burkitt lymphoma, we performed RNAi-based, loss-of-function screening in eight Burkitt lymphoma cell lines and integrated non-Burkitt lymphoma RNAi screens and genetic data. We identified 76 genes essential to Burkitt lymphoma, including genes associated with hematopoietic cell differentiation (

Identifiants

DOI: 10.1158/0008-5472.CAN-18-3438 PMID: 31000522
pubmed: 31000522
pii: 0008-5472.CAN-18-3438
doi: 10.1158/0008-5472.CAN-18-3438
doi:

Substances chimiques

Cell Cycle Proteins 0
MDM4 protein, human 0
Proto-Oncogene Proteins 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3125-3138

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Jennifer Hüllein (J)

Molecular Therapy in Hematology and Oncology & Department of Translational Oncology, NCT and DKFZ, Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.

Mikołaj Słabicki (M)

Molecular Therapy in Hematology and Oncology & Department of Translational Oncology, NCT and DKFZ, Heidelberg, Germany.

Maciej Rosolowski (M)

Department for Statistics and Epidemiology, Institute for Medical Informatics, Leipzig, Germany.

Alexander Jethwa (A)

Molecular Therapy in Hematology and Oncology & Department of Translational Oncology, NCT and DKFZ, Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.

Stefan Habringer (S)

III. Medical Department of Hematology and Medical Oncology, Technical University of Munich, Germany.

Katarzyna Tomska (K)

Molecular Therapy in Hematology and Oncology & Department of Translational Oncology, NCT and DKFZ, Heidelberg, Germany.

Roma Kurilov (R)

Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany.

Junyan Lu (J)

European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.

Sebastian Scheinost (S)

Molecular Therapy in Hematology and Oncology & Department of Translational Oncology, NCT and DKFZ, Heidelberg, Germany.

Rabea Wagener (R)

Institute of Human Genetics, Ulm University & Ulm University Medical Center, Germany.
Institute of Human Genetics, University of Kiel, Kiel, Germany.

Zhiqin Huang (Z)

Division of Molecular Genetics, DKFZ, Heidelberg, Germany.

Marina Lukas (M)

Molecular Therapy in Hematology and Oncology & Department of Translational Oncology, NCT and DKFZ, Heidelberg, Germany.

Olena Yavorska (O)

European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.

Hanne Helfrich (H)

Department of Internal Medicine III, University of Ulm, Ulm, Germany.

René Scholtysik (R)

Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Medical School, Essen, Germany, and the German Cancer Consortium (DKTK).

Kyle Bonneau (K)

Cellecta, Inc., Mountain View, California.

Donato Tedesco (D)

Cellecta, Inc., Mountain View, California.
ORCID: 0000-0001-8525-0997

Ralf Küppers (R)

Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Medical School, Essen, Germany, and the German Cancer Consortium (DKTK).
ORCID: 0000-0002-6691-7191

Wolfram Klapper (W)

Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel, Kiel, Germany.

Christiane Pott (C)

Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Stephan Stilgenbauer (S)

Department of Internal Medicine III, University of Ulm, Ulm, Germany.

Birgit Burkhardt (B)

Department of Pediatric Hematology and Oncology, NHL-BFM Study Center, University Children's Hospital, Münster, Germany.
ORCID: 0000-0002-1151-829X

Markus Löffler (M)

Department for Statistics and Epidemiology, Institute for Medical Informatics, Leipzig, Germany.

Lorenz H Trümper (LH)

Department of Hematology and Medical Oncology, Göttingen University Medical Center, Göttingen, Germany.

Michael Hummel (M)

Institute of Pathology, Charité-University Medicine Berlin, Berlin, Germany.

Benedikt Brors (B)

Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany.

Marc Zapatka (M)

Division of Molecular Genetics, DKFZ, Heidelberg, Germany.

Reiner Siebert (R)

Institute of Human Genetics, Ulm University & Ulm University Medical Center, Germany.
Institute of Human Genetics, University of Kiel, Kiel, Germany.

Markus Kreuz (M)

Department for Statistics and Epidemiology, Institute for Medical Informatics, Leipzig, Germany.

Ulrich Keller (U)

III. Medical Department of Hematology and Medical Oncology, Technical University of Munich, Germany.
Division of Hematology and Oncology at Campus Benjamin Franklin (CBF), Charité, Berlin, Germany.

Wolfgang Huber (W)

European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.

Thorsten Zenz (T)

Molecular Therapy in Hematology and Oncology & Department of Translational Oncology, NCT and DKFZ, Heidelberg, Germany. thorsten.zenz@usz.ch.
Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome B › Lymphome de Burkitt › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Cycle cellulaire › Points de contrôle du cycle cellulaire › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du cycle cellulaire › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Aberrations des chromosomes › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Chromosomes › Chromosomes de mammifère › Chromosomes humains › Chromosomes humains 1-3 › Chromosomes humains de la paire 1 › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › MDM4 Is Targeted by 1q Gain and Drives Disease...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › MDM4 Is Targeted by 1q Gain and Drives Disease...